BRPI0615158A8 - composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto. - Google Patents

composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.

Info

Publication number
BRPI0615158A8
BRPI0615158A8 BRPI0615158A BRPI0615158A BRPI0615158A8 BR PI0615158 A8 BRPI0615158 A8 BR PI0615158A8 BR PI0615158 A BRPI0615158 A BR PI0615158A BR PI0615158 A BRPI0615158 A BR PI0615158A BR PI0615158 A8 BRPI0615158 A8 BR PI0615158A8
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
disease
treating
Prior art date
Application number
BRPI0615158A
Other languages
English (en)
Inventor
Mangano Giorgina
Furlotti Guido
Coletta Isabella
Polenzani Lorenzo
Alessandra Alisi Maria
Cazzolla Nicola
Dragone Patrizia
Russo Vincenzo
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of BRPI0615158A2 publication Critical patent/BRPI0615158A2/pt
Publication of BRPI0615158A8 publication Critical patent/BRPI0615158A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

composto de 3-aminocarbazol, composição farmacêutica, uso de um composto de 3-aminocarbazol, e, método para preparar um composto. um composto da fórmula (i), em que r1, r2, r3, r4, r5, r6, x e y têm os significados indicados no relatório descritivo, e os sais farmaceuticamente aceitáveis deste. uma composição farmacêutica contendo um composto da fórmula (i) ou um sal farmaceuticamente aceitável deste. um método para preparar o composto acima mencionado da fórmula (i) e os sais farmaceuticamente aceitáveis deste.
BRPI0615158A 2005-08-03 2006-07-25 composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto. BRPI0615158A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2005A001523 2005-08-03
IT001523A ITMI20051523A1 (it) 2005-08-03 2005-08-03 Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
PCT/EP2006/007393 WO2007014687A1 (en) 2005-08-03 2006-07-25 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof

Publications (2)

Publication Number Publication Date
BRPI0615158A2 BRPI0615158A2 (pt) 2011-05-03
BRPI0615158A8 true BRPI0615158A8 (pt) 2018-03-06

Family

ID=35501077

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615158A BRPI0615158A8 (pt) 2005-08-03 2006-07-25 composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.

Country Status (23)

Country Link
US (2) US7879900B2 (pt)
EP (1) EP1910288B1 (pt)
JP (1) JP5274252B2 (pt)
KR (1) KR101278620B1 (pt)
CN (1) CN101223139B (pt)
AR (1) AR056014A1 (pt)
AT (1) ATE471930T1 (pt)
AU (1) AU2006275063B2 (pt)
BR (1) BRPI0615158A8 (pt)
CA (1) CA2609441C (pt)
DE (1) DE602006015062D1 (pt)
DK (1) DK1910288T3 (pt)
EA (1) EA012786B1 (pt)
ES (1) ES2345944T3 (pt)
GE (1) GEP20104964B (pt)
IL (1) IL187713A (pt)
IT (1) ITMI20051523A1 (pt)
MX (1) MX2008001551A (pt)
PL (1) PL1910288T3 (pt)
PT (1) PT1910288E (pt)
SI (1) SI1910288T1 (pt)
UA (1) UA93378C2 (pt)
WO (1) WO2007014687A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2119705A1 (en) 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
GB0812185D0 (en) 2008-07-03 2008-08-13 Dow Corning Polymers modified by silanes
GB0812186D0 (en) 2008-07-03 2008-08-13 Dow Corning Modified polyolefins
EP2323982B1 (en) 2008-08-15 2012-02-29 Georgetown University Fluorescent regulators of rassf1a expression and human cancer cell proliferation
GB201000121D0 (en) 2010-01-06 2010-02-17 Dow Corning Modified polyolefins
GB201000128D0 (en) 2010-01-06 2010-02-24 Dow Corning Modified polymers
GB201000117D0 (en) 2010-01-06 2010-02-17 Dow Corning Organopolysiloxanes containing an unsaturated group
GB201000120D0 (en) 2010-01-06 2010-02-17 Dow Corning Process for forming crosslinked and branched polymers
GB201006846D0 (en) 2010-04-23 2010-06-09 Glaxo Group Ltd Novel compounds
MX2010014124A (es) * 2010-12-17 2012-06-18 Gabriel Diaz Hernandez Solución antiséptica local de amplio espectro a base de hipodorito de sodio, bicarbonato de sodio, cloramfenicol, jabón y solución salina al 0.9%.
FR2972193B1 (fr) 2011-03-04 2014-07-04 Setup Performance Polyolefines modifiees, reticulables apres transformation, et procede de fabrication desdites polyolefines
US10376672B2 (en) 2013-03-15 2019-08-13 Auris Health, Inc. Catheter insertion system and method of fabrication
US11053255B2 (en) 2015-06-22 2021-07-06 Georgetown University Synthesis of mahanine and related compounds
EP4125874A4 (en) * 2020-03-25 2024-05-01 SRI International LIPOXYGENASE INHIBITORS
CN112159345B (zh) * 2020-11-18 2023-08-25 湖北和昌新材料科技股份有限公司 N-乙基咔唑的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
CA2381111A1 (en) * 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
IL156487A0 (en) 2000-12-22 2004-01-04 Astrazeneca Ab Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE10125961A1 (de) * 2001-05-29 2002-12-12 Boehringer Ingelheim Int Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden
CA2403307A1 (en) * 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ITMI20050909A1 (it) 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-

Also Published As

Publication number Publication date
AU2006275063A1 (en) 2007-02-08
JP5274252B2 (ja) 2013-08-28
IL187713A0 (en) 2008-08-07
ES2345944T3 (es) 2010-10-06
CN101223139B (zh) 2010-11-17
CN101223139A (zh) 2008-07-16
DK1910288T3 (da) 2010-10-11
KR20080040691A (ko) 2008-05-08
EP1910288B1 (en) 2010-06-23
KR101278620B1 (ko) 2013-06-25
US20080207727A1 (en) 2008-08-28
US20110046197A1 (en) 2011-02-24
AR056014A1 (es) 2007-09-12
PL1910288T3 (pl) 2010-11-30
CA2609441A1 (en) 2007-02-08
HK1112916A1 (en) 2008-09-19
UA93378C2 (ru) 2011-02-10
EA200800502A1 (ru) 2008-06-30
WO2007014687A1 (en) 2007-02-08
US8207214B2 (en) 2012-06-26
EA012786B1 (ru) 2009-12-30
AU2006275063B2 (en) 2012-03-08
ITMI20051523A1 (it) 2007-02-04
SI1910288T1 (sl) 2010-10-29
CA2609441C (en) 2013-09-03
MX2008001551A (es) 2008-04-22
DE602006015062D1 (de) 2010-08-05
US7879900B2 (en) 2011-02-01
GEP20104964B (en) 2010-04-26
BRPI0615158A2 (pt) 2011-05-03
IL187713A (en) 2011-09-27
JP2009502999A (ja) 2009-01-29
ATE471930T1 (de) 2010-07-15
PT1910288E (pt) 2010-08-18
EP1910288A1 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
BRPI0615158A8 (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
BR112012010124B8 (pt) composto derivado de cromenona ou um sal farmaceuticamente aceitavel do mesmo que possui atividade antitumor
SE0402735D0 (sv) Novel compounds
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
TW200716628A (en) Novel compounds
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
BRPI0414780B8 (pt) composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0513713A (pt) derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
BRPI0821116B8 (pt) composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
BRPI0515897A (pt) composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
EA200501164A1 (ru) Индазоламиды с аналгетической активностью

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.